Vicarious Surgical Inc.

NYSE:RBOT Stock Report

Market Cap: US$67.8m

Vicarious Surgical Valuation

Is RBOT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RBOT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RBOT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RBOT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RBOT?

Key metric: As RBOT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RBOT. This is calculated by dividing RBOT's market cap by their current book value.
What is RBOT's PB Ratio?
PB Ratio1.2x
BookUS$57.88m
Market CapUS$67.76m

Price to Book Ratio vs Peers

How does RBOT's PB Ratio compare to its peers?

The above table shows the PB ratio for RBOT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average7374.9x
IRME IR-Med
29468.4x86.4%US$58.9m
MDNC Medinotec
22.4xn/aUS$58.7m
NVNO enVVeno Medical
1.3x32.9%US$59.8m
ECOR electroCore
7.6x70.2%US$72.3m
RBOT Vicarious Surgical
1.2x-3.8%US$67.8m

Price-To-Book vs Peers: RBOT is good value based on its Price-To-Book Ratio (1.2x) compared to the peer average (9825.8x).

Price to Book Ratio vs Industry

How does RBOT's PB Ratio compare vs other companies in the US Medical Equipment Industry?

28 CompaniesPrice / BookEstimated GrowthMarket Cap
ADGM Adagio Medical Holdings
0.5xn/aUS$35.90m
MHUA Meihua International Medical Technologies
0.1xn/aUS$18.77m
RVP Retractable Technologies
0.2xn/aUS$18.72m
LFWD Lifeward
0.5x65.0%US$16.82m
RBOT 1.2xIndustry Avg. 2.5xNo. of Companies28PB0246810+
28 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: RBOT is good value based on its Price-To-Book Ratio (1.2x) compared to the US Medical Equipment industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is RBOT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RBOT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RBOT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RBOT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.49
US$11.17
-2.8%
11.8%US$13.00US$10.00n/a3
Nov ’25US$8.08
US$9.50
+17.6%
23.9%US$12.00US$6.50n/a3
Oct ’25US$5.43
US$9.50
+75.0%
23.9%US$12.00US$6.50n/a3
Sep ’25US$6.31
US$9.50
+50.6%
23.9%US$12.00US$6.50n/a3
Aug ’25US$6.38
US$28.33
+344.1%
50.6%US$45.00US$10.00n/a3
Jul ’25US$5.40
US$31.00
+474.1%
35.6%US$45.00US$18.00n/a3
Jun ’25US$9.45
US$31.00
+227.9%
35.6%US$45.00US$18.00n/a3
May ’25US$8.43
US$31.00
+267.7%
35.6%US$45.00US$18.00n/a3
Apr ’25US$8.78
US$31.00
+253.2%
35.6%US$45.00US$18.00n/a3
Mar ’25US$10.95
US$36.00
+228.7%
35.4%US$45.00US$18.00n/a3
Feb ’25US$12.85
US$36.00
+180.1%
35.4%US$45.00US$18.00n/a3
Jan ’25US$11.00
US$36.00
+227.2%
35.4%US$45.00US$18.00n/a3
Nov ’24US$11.41
US$210.00
+1,740.7%
26.7%US$270.00US$120.00US$8.084
Oct ’24US$17.72
US$210.00
+1,085.0%
26.7%US$270.00US$120.00US$5.434
Sep ’24US$29.23
US$210.00
+618.4%
26.7%US$270.00US$120.00US$6.314
Aug ’24US$48.60
US$210.00
+332.1%
26.7%US$270.00US$120.00US$6.384
Jul ’24US$54.90
US$210.00
+282.5%
26.7%US$270.00US$120.00US$5.404
Jun ’24US$66.00
US$210.00
+218.2%
26.7%US$270.00US$120.00US$9.454
May ’24US$70.80
US$232.50
+228.4%
36.9%US$360.00US$120.00US$8.434
Apr ’24US$68.10
US$232.50
+241.4%
36.9%US$360.00US$120.00US$8.784
Mar ’24US$78.90
US$232.50
+194.7%
36.9%US$360.00US$120.00US$10.954
Feb ’24US$89.70
US$292.50
+226.1%
40.6%US$450.00US$150.00US$12.854
Jan ’24US$60.60
US$292.50
+382.7%
40.6%US$450.00US$150.00US$11.004
Dec ’23US$102.30
US$292.50
+185.9%
40.6%US$450.00US$150.00US$8.594
Nov ’23US$117.00
US$292.50
+150.0%
40.6%US$450.00US$150.00US$11.414

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

7D

0.5%

1Y

-15.9%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.37

7D

5.1%

1Y

-18.8%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

7D

2.5%

1Y

101.6%